Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
GlobeNewswire · 财报与经营业绩 · November 4, 2026 at 7:30 AM ET
Read the full report at the original publisher.